Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design)

Abstract

In this article, we present the rationale and design of the Sildenafil HF trial (ClinicalTrials.govidentifier: NCT02304705). We will randomize patients with heart failure and reactive pulmonary hypertension (pulmonary capillary wedge pressure > 15 mmHg, pulmonary vascular resistance > 3 Wood units) into two groups: the treatment group receiving sildenafil 20 mg 3 times a day and a matching placebo group. The duration of intervention will be 3 months. The primary outcome is 6-minute walk distance. Key features of this trial include (1) that reactive pulmonary hypertension is an inclusion criterion, (2) that patients will be enrolled regardless of left ventricular ejection fraction, and (3) that clinical stability in the 3 months preceding enrollment is not required.

Read the full article online

Topics

Heart Arrest/ Block/ Defects/ Diseases/ Failure/ Rate/ Infarction
Pulmonary Hypertension

Authors

Maya Guglin, Navin Rajagopalan, Paul Anaya, Richard Charnigo

Published in:

Pulmonary Circulation Vol 6: No 2 cover image

June 2016

Pulmonary Circulation Vol 6: No 2

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg